Serina Therapeutics, Inc. Cash Flow Statement
SER|7 years of annual SEC 10-K data (FY2018-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$18M
FY2025
Free Cash Flow
-$18M
FY2025
Capital Expenditures
$59,000
Cash used for long-term assets
Dividends Paid
N/A
FY2025
Serina Therapeutics, Inc. used $18M in operating cash flow and negative free cash flow of $18M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 1/9 criteria passed
- Negative shareholders equity: Liabilities exceed assets
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2018 |
|---|---|---|---|---|---|---|---|
| Net Income | -$19.2M | $5.3M | $5.3M | -$10.5M | -$8.7M | -$12.2M | -$7.5M |
| Depreciation & Amortization | $100.0K | $90.0K | $90.0K | - | - | $393.0K | - |
| Operating Cash Flow | -$18.0M | -$2.5M | -$2.5M | -$5.9M | -$7.9M | -$10.2M | -$8.0M |
| Capital Expenditures | $59.0K | $504.0K | $504.0K | - | - | $641.0K | $21.0K |
| Free Cash Flow | -$18.0M | -$3.0M | -$3.0M | - | - | -$10.8M | -$8.0M |
| FCF Margin | -13856.9% | -94.5% | -94.5% | - | - | -625.1% | -574.2% |